Hvivo
HVO · AIM · Health Care · mcap £41m · 6.0p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 22 Sep 26 | Board change | Directorate Change
London, UK – 22 September 2026, hVIVO plc (AIM: HVO), a purpose-built, full-service international clinical development partner and the world leader in human challenge trials, today announces the following changes to the |
−0.8% |
| 15 Sep 26 | Results | Half-year Results
Contracted orderbook more than doubles in H1 2026 |
−4.7% |
| 15 Sep 26 | Board change | Chief Financial Officer Succession
Richard Cotton appointed Interim CFO as permanent CFO search enters final stages |
−4.7% |
| 27 Aug 26 | HVIVO acquires CRS Berlin
London, UK - 27 August 2026, hVIVO plc (AIM: HVO), a purpose-built, full-service international clinical development partner and the world leader in human challenge trials, announces the acquisition of CRS Clinical Resear |
+1.6% | |
| 27 Aug 26 | HVIVO acquires CRS Berlin, expanding expertise into dermatology and women's health markets
London, UK – 27 August 2026, hVIVO plc (AIM: HVO), a purpose-built, full-service international clinical development partner and the world leader in human challenge trials, announces the acquisition of CRS Clinical Resear |
+1.6% | |
| 23 Jul 26 | Trading update | H1 2026 Trading Update
Strong commercial momentum drives more than doubling of orderbook |
−0.7% |
| 13 Jul 26 | Change of Auditor
London, UK - 13 July 2026, the board of hVIVO plc (AIM: HVO), a purpose built, full-service international clinical development partner and the world leader in human challenge trials, has agreed to appoint Grant Thornton |
+0.0% | |
| 01 Jun 26 | Consultancy contract with Decoy Therapeutics
Consultancy contract signed with Decoy Therapeutics to support development of respiratory antiviral candidates |
−0.6% | |
| 20 May 26 | Capital Markets Day
hVIVO to showcase integrated, full service early clinical development platform at Capital Markets Day |
+0.6% | |
| 07 May 26 | £6m Influenza HCT contract signed
£6m Influenza HCT contract signed with clinical-stage biopharmaceutical company |
+8.0% | |
| 22 Apr 26 | HCT contract signed with ILiAD Biotechnologies
hVIVO to conduct world's first pivotal Phase III human challenge |
−0.5% | |
| 17 Apr 26 | Results | Annual Report & Notice of AGM
London, UK - 17 April 2026, hVIVO plc (AIM: HVO), a purpose-built, full-service international clinical development partner and the world leader in human challenge trials, confirms that the Company's Annual Report and Acc |
+4.7% |
| 15 Apr 26 | Results | Final Results
Integrated clinical development platform established following a year of strategic progress |
−2.9% |
| 14 Apr 26 | HVIVO launches unified brand identity
hVIVO launches unified brand identity reflecting strategic transformation into integrated clinical development partner |
+17.6% | |
| 14 Apr 26 | Influenza HCT contract signed with Traws Pharma
London, UK - 14 April 2026, hVIVO plc (AIM: HVO), a purpose-built, full-service international clinical development partner and the world leader in human challenge trials, announces that it has signed a Clinical Trial Agr |
+17.6% | |
| 29 Jan 26 | Trading update | Trading Update
FY25 revenue in line and positive adjusted EBITDA |
+3.3% |
| 27 Jan 26 | Notice of Trading Update
hVIVO plc (AIM: HVO), a full-service early phase Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, confirms that it will issue a trading update for the year ended 31 December 2 |
+1.7% | |
| 18 Dec 25 | Board change | Appointment of Non-Executive Director
hVIVO strengthens Board with appointment of Richard Cotton as |
+6.9% |
| 15 Dec 25 | Board change | CEO & CFO Share Purchase
hVIVO plc (AIM: HVO), a full-service early phase Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces that on 15 December 2025, Yamin 'Mo' Khan, Chief Executive Officer |
+25.5% |
| 27 Nov 25 | MSD to acquire Cidara
MSD to acquire Cidara following Positive Results from Phase IIb Trial |
−1.7% | |
| 20 Nov 25 | >£5 million CRS contracts signed
hVIVO plc (AIM: HVO), a full-service early phase Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces its German subsidiary CRS, has signed contracts worth over £5 milli |
+0.8% | |
| 11 Nov 25 | Positive data from novel human challenge models
Positive data from multiple novel human challenge models |
+2.4% | |
| 03 Nov 25 | Presentation at Jefferies Healthcare Conference
hVIVO to present at Jefferies Global Healthcare Conference |
−0.5% |
Company filings. Not investment advice.